Last reviewed · How we verify

Tibolone plus Xiangshao granules — Competitive Intelligence Brief

Tibolone plus Xiangshao granules (Tibolone plus Xiangshao granules) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hormone replacement therapy (HRT) / Selective tissue estrogenic activity regulator (STEAR). Area: Gynecology / Endocrinology.

marketed Hormone replacement therapy (HRT) / Selective tissue estrogenic activity regulator (STEAR) Estrogen receptor, Progesterone receptor, Androgen receptor Gynecology / Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Tibolone plus Xiangshao granules (Tibolone plus Xiangshao granules) — Peking Union Medical College Hospital. Tibolone acts as a selective tissue estrogenic activity regulator (STEAR) with progestin and androgen activity, while Xiangshao granules provide traditional Chinese medicine support for menopausal symptoms.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tibolone plus Xiangshao granules TARGET Tibolone plus Xiangshao granules Peking Union Medical College Hospital marketed Hormone replacement therapy (HRT) / Selective tissue estrogenic activity regulator (STEAR) Estrogen receptor, Progesterone receptor, Androgen receptor
fenofibrate and tibolone fenofibrate and tibolone Keogh Institute for Medical Research marketed Fibrate + Selective Estrogen Receptor Modulator (SERM) PPAR-α (fenofibrate); Estrogen receptor, progesterone receptor, androgen receptor (tibolone)
Tibolone (Livial) Tibolone (Livial) Wyeth is now a wholly owned subsidiary of Pfizer marketed Selective tissue estrogenic activity regulator (STEAR); synthetic steroid Estrogen receptor, progesterone receptor, androgen receptor
Add back therapy 1 (tibolone) Add back therapy 1 (tibolone) University of Cagliari marketed Selective Tissue Estrogenic Activity Regulator (STEAR); Hormone Replacement Therapy Estrogen receptor, Progesterone receptor, Androgen receptor
ethinyl estradiol and cyproterone acetate ethinyl estradiol and cyproterone acetate S.C.B. Medical College and Hospital marketed Combined oral contraceptive with anti-androgenic activity Estrogen receptor, progesterone receptor, androgen receptor
Black Cohosh (iCR) or tibolone Black Cohosh (iCR) or tibolone Schaper & Bruemmer GmbH & Co KG phase 3 Herbal extract / Selective tissue estrogenic activity regulator (STEAR) Serotonin receptors (Black Cohosh); estrogen receptor, progesterone receptor, androgen receptor (tibolone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hormone replacement therapy (HRT) / Selective tissue estrogenic activity regulator (STEAR) class)

  1. Peking Union Medical College Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tibolone plus Xiangshao granules — Competitive Intelligence Brief. https://druglandscape.com/ci/tibolone-plus-xiangshao-granules. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: